Araştırma Makalesi
BibTex RIS Kaynak Göster
Yıl 2018, Cilt: 4 Sayı: 2, 79 - 84, 04.04.2018
https://doi.org/10.18621/eurj.341363

Öz

Kaynakça

  • [1] Fendler A, Jung M, Stephan C, Honey RJ, Stewart RJ, Pace KT, et al. miRNAs can predict prostate cancer biochemical relapse and are involved in tumor progression. Int J Oncol 2011;39:1183-92.
  • [2] Masko EM, Alfaqih MA, Solomon KR, Barry WT, Newgard CB, Muehlbauer MJ, et al. Evidence for feedback regulation following cholesterol lowering therapy in a prostate cancer xenograft model. Prostate 2017;77:446-57.
  • [3] Van Hemelrijck M, Walldius G, Jungner I, Hammar N, Garmo H, Binda E, et al. Low levels of apolipoprotein A-I and HDL are associated with risk of prostate cancer in the Swedish AMORIS study. Cancer Causes Control 2011;22:1011-9.
  • [4] Farwell WR, D'Avolio LW, Scranton RE, Lawler EV, Gaziano JM. Statins and prostate cancer diagnosis and grade in a veterans population. J Natl Cancer Inst 2011;103:885-92.
  • [5] Mondul A, Weinstein S, Virtamo J, Albanes D. Serum total and HDL cholesterol and risk of prostate cancer. Cancer Causes Control 2011;22:1545-52.
  • [6] Allott EH, Howard LE, Cooperberg MR, Kane CJ, Aronson WJ, Terris MK, et al. Postoperative statin use and risk of biochemical recurrence following radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. BJU Int 2014;114:661-6.
  • [7] Dillard PR, Lin MF, Khan SA. Androgen-independent prostate cancer cells acquire the complete steroidogenic potential of synthesizing testosterone from cholesterol. Mol Cell Endocrinol 2008;295:115-20.
  • [8] Krycer JR, Phan L, Brown AJ. A key regulator of cholesterol homoeostasis, SREBP-2, can be targeted in prostate cancer cells with natural products. Biochem J 2012;446:191-201.
  • [9] Bommer GT, MacDougald OA. Regulation of lipid homeostasis by the bifunctional SREBF2-miR33a locus. Cell Metab 2011;13:241-7.
  • [10] Karatas O, Wang J, Shao L, Ozen M, Zhang Y, Creighton C, et al. miR-33a is a tumor suppressor microRNA that is decreased in prostate cancer. Oncotarget 2017;8:60243-56.
  • [11] Najafi-Shoushtari SH, Kristo F, Li Y, Shioda T, Cohen DE, Gerszten RE, Naar AM. MicroRNA-33 and the SREBP host genes cooperate to control cholesterol homeostasis. Science 2010;328:1566-9.
  • [12] Kuo PL, Liao SH, Hung JY, Huang MS, Hsu YL. MicroRNA-33a functions as a bone metastasis suppressor in lung cancer by targeting parathyroid hormone related protein. Biochim Biophys Acta 2013;1830:3756-66.
  • [13] Zhang C, Zhang Y, Ding W, Lin Y, Huang Z, Luo Q. MiR-33a suppresses breast cancer cell proliferation and metastasis by targeting ADAM9 and ROS1. Protein Cell 2015;6:881-9.
  • [14] Liang C, Yu XJ, Guo XZ, Sun MH, Wang Z, Song Y, et al. MicroRNA-33a-mediated downregulation of Pim-3 kinase expression renders human pancreatic cancer cells sensitivity to gemcitabine. Oncotarget 2015;6:14440-55.
  • [15] Zhang J, Wang D, Xiong J, Chen L, Huang J. MicroRNA-33a-5p suppresses growth of osteosarcoma cells and is downregulated in human osteosarcoma. Oncol Lett 2015;10:2135-41.
  • [16] Zhou J, Xu D, Xie H, Tang J, Liu R, Li J, et al. miR-33a functions as a tumor suppressor in melanoma by targeting HIF-1α. Cancer Biol Ther 2015;16:846-55.
  • [17] Kang J, Kim W, Lee S, Kwon D, Chun J, Son B, et al. TFAP2C promotes lung tumorigenesis and aggressiveness through miR-183- and miR-33a-mediated cell cycle regulation. Oncogene 2017;36:1585-96.
  • [18] Yang L, Yang J, Li J, Shen X, Le Y, Zhou C, et al. MircoRNA-33a inhibits epithelial-to-mesenchymal transition and metastasis and could be a prognostic marker in non-small cell lung cancer. Sci Rep 2015;5:13677.
  • [19] Li X, Wu JB, Li Q, Shigemura K, Chung LW, Huang WC. SREBP-2 promotes stem cell-like properties and metastasis by transcriptional activation of c-Myc in prostate cancer. Oncotarget 2016;7:12869-84.
  • [20] Gerin I, Clerbaux LA, Haumont O, Lanthier N, Das AK, Burant CF, et al. Expression of miR-33 from an SREBP2 intron inhibits cholesterol export and fatty acid oxidation. J Biol Chem 2010;285:33652-61.
  • [21] Horie T, Ono K, Horiguchi M, Nishi H, Nakamura T, Nagao K, et al. MicroRNA-33 encoded by an intron of sterol regulatory element-binding protein 2 (Srebp2) regulates HDL in vivo. Proc Natl Acad Sci U S A 2010;107:17321-6.
  • [22] Marquart TJ, Allen RM, Ory DS, Baldán A. miR-33 links SREBP-2 induction to repression of sterol transporters. Proc Natl Acad Sci U S A 2010;107:12228-32.
  • [23] Najafi-Shoushtari SH, Kristo F, Li Y, Shioda T, Cohen DE, Gerszten RE, et al. MicroRNA-33 and the SREBP host genes cooperate to control cholesterol homeostasis. Science 2010;328:1566-9.
  • [24] Lee BH, Taylor MG, Robinet P, Smith JD, Schweitzer J, Sehayek E, et al. Dysregulation of cholesterol homeostasis in human prostate cancer through loss of ABCA1. Cancer Res 2013;73:1211-8.

MicroRNA-33a levels do not correlate with the expression of its host gene SREBF2 and its isoforms in prostate cancer cell lines

Yıl 2018, Cilt: 4 Sayı: 2, 79 - 84, 04.04.2018
https://doi.org/10.18621/eurj.341363

Öz

Objectives. Prostate cancer
is currently the most frequently diagnosed
malignant
neoplasm
and the second leading cause of cancer related
mortality in men over the age of 50 years in the developed countries. MicroRNA-33a
(miR-33a), localized within the intron 16 of SREBF2, has been reported to have tumor suppressive properties in
some cancers including prostate cancer, whereas its host gene, SREBF2, has been
shown to be elevated in prostate cancer and to act as an oncogene. Due to the
paradoxical expression of an oncogene and a tumor suppressor from a single
genetic locus, there is a need for evaluation of miR-33a and SREBF2 expression
status in prostate cancer cells to help understanding their roles in prostate
carcinogenesis. Methods. In this study, we aimed at investigating the link
between the expressions of miR-33a and its host gene SREBF2 and its isoforms in
prostate cancer cell lines using quantitative real time PCR. We evaluated the
relative expression levels with using 2- ΔΔCT method and tested the
correlations of microRNA and gene expressions with Pearson’s Correlation test
using GraphPad Prism 6. Results. Our results demonstrated
variable expression levels for SREBF2 mRNA and miR-33a expression levels in
prostate cancer cell lines, with some decreased, some increased and some
unchanged. Further analysis showed a strong correlation among expressions of
SREBF2 isoforms though we could not find a significant association between
levels of SREBF2 isoforms and miR-33a expression. Conclusion. This data
suggest possible posttranscriptional regulation of miR-33a expression in
prostate cancer.

Kaynakça

  • [1] Fendler A, Jung M, Stephan C, Honey RJ, Stewart RJ, Pace KT, et al. miRNAs can predict prostate cancer biochemical relapse and are involved in tumor progression. Int J Oncol 2011;39:1183-92.
  • [2] Masko EM, Alfaqih MA, Solomon KR, Barry WT, Newgard CB, Muehlbauer MJ, et al. Evidence for feedback regulation following cholesterol lowering therapy in a prostate cancer xenograft model. Prostate 2017;77:446-57.
  • [3] Van Hemelrijck M, Walldius G, Jungner I, Hammar N, Garmo H, Binda E, et al. Low levels of apolipoprotein A-I and HDL are associated with risk of prostate cancer in the Swedish AMORIS study. Cancer Causes Control 2011;22:1011-9.
  • [4] Farwell WR, D'Avolio LW, Scranton RE, Lawler EV, Gaziano JM. Statins and prostate cancer diagnosis and grade in a veterans population. J Natl Cancer Inst 2011;103:885-92.
  • [5] Mondul A, Weinstein S, Virtamo J, Albanes D. Serum total and HDL cholesterol and risk of prostate cancer. Cancer Causes Control 2011;22:1545-52.
  • [6] Allott EH, Howard LE, Cooperberg MR, Kane CJ, Aronson WJ, Terris MK, et al. Postoperative statin use and risk of biochemical recurrence following radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. BJU Int 2014;114:661-6.
  • [7] Dillard PR, Lin MF, Khan SA. Androgen-independent prostate cancer cells acquire the complete steroidogenic potential of synthesizing testosterone from cholesterol. Mol Cell Endocrinol 2008;295:115-20.
  • [8] Krycer JR, Phan L, Brown AJ. A key regulator of cholesterol homoeostasis, SREBP-2, can be targeted in prostate cancer cells with natural products. Biochem J 2012;446:191-201.
  • [9] Bommer GT, MacDougald OA. Regulation of lipid homeostasis by the bifunctional SREBF2-miR33a locus. Cell Metab 2011;13:241-7.
  • [10] Karatas O, Wang J, Shao L, Ozen M, Zhang Y, Creighton C, et al. miR-33a is a tumor suppressor microRNA that is decreased in prostate cancer. Oncotarget 2017;8:60243-56.
  • [11] Najafi-Shoushtari SH, Kristo F, Li Y, Shioda T, Cohen DE, Gerszten RE, Naar AM. MicroRNA-33 and the SREBP host genes cooperate to control cholesterol homeostasis. Science 2010;328:1566-9.
  • [12] Kuo PL, Liao SH, Hung JY, Huang MS, Hsu YL. MicroRNA-33a functions as a bone metastasis suppressor in lung cancer by targeting parathyroid hormone related protein. Biochim Biophys Acta 2013;1830:3756-66.
  • [13] Zhang C, Zhang Y, Ding W, Lin Y, Huang Z, Luo Q. MiR-33a suppresses breast cancer cell proliferation and metastasis by targeting ADAM9 and ROS1. Protein Cell 2015;6:881-9.
  • [14] Liang C, Yu XJ, Guo XZ, Sun MH, Wang Z, Song Y, et al. MicroRNA-33a-mediated downregulation of Pim-3 kinase expression renders human pancreatic cancer cells sensitivity to gemcitabine. Oncotarget 2015;6:14440-55.
  • [15] Zhang J, Wang D, Xiong J, Chen L, Huang J. MicroRNA-33a-5p suppresses growth of osteosarcoma cells and is downregulated in human osteosarcoma. Oncol Lett 2015;10:2135-41.
  • [16] Zhou J, Xu D, Xie H, Tang J, Liu R, Li J, et al. miR-33a functions as a tumor suppressor in melanoma by targeting HIF-1α. Cancer Biol Ther 2015;16:846-55.
  • [17] Kang J, Kim W, Lee S, Kwon D, Chun J, Son B, et al. TFAP2C promotes lung tumorigenesis and aggressiveness through miR-183- and miR-33a-mediated cell cycle regulation. Oncogene 2017;36:1585-96.
  • [18] Yang L, Yang J, Li J, Shen X, Le Y, Zhou C, et al. MircoRNA-33a inhibits epithelial-to-mesenchymal transition and metastasis and could be a prognostic marker in non-small cell lung cancer. Sci Rep 2015;5:13677.
  • [19] Li X, Wu JB, Li Q, Shigemura K, Chung LW, Huang WC. SREBP-2 promotes stem cell-like properties and metastasis by transcriptional activation of c-Myc in prostate cancer. Oncotarget 2016;7:12869-84.
  • [20] Gerin I, Clerbaux LA, Haumont O, Lanthier N, Das AK, Burant CF, et al. Expression of miR-33 from an SREBP2 intron inhibits cholesterol export and fatty acid oxidation. J Biol Chem 2010;285:33652-61.
  • [21] Horie T, Ono K, Horiguchi M, Nishi H, Nakamura T, Nagao K, et al. MicroRNA-33 encoded by an intron of sterol regulatory element-binding protein 2 (Srebp2) regulates HDL in vivo. Proc Natl Acad Sci U S A 2010;107:17321-6.
  • [22] Marquart TJ, Allen RM, Ory DS, Baldán A. miR-33 links SREBP-2 induction to repression of sterol transporters. Proc Natl Acad Sci U S A 2010;107:12228-32.
  • [23] Najafi-Shoushtari SH, Kristo F, Li Y, Shioda T, Cohen DE, Gerszten RE, et al. MicroRNA-33 and the SREBP host genes cooperate to control cholesterol homeostasis. Science 2010;328:1566-9.
  • [24] Lee BH, Taylor MG, Robinet P, Smith JD, Schweitzer J, Sehayek E, et al. Dysregulation of cholesterol homeostasis in human prostate cancer through loss of ABCA1. Cancer Res 2013;73:1211-8.
Toplam 24 adet kaynakça vardır.

Ayrıntılar

Birincil Dil İngilizce
Konular Sağlık Kurumları Yönetimi
Bölüm Original Article
Yazarlar

Ömer Faruk Karataş

Michael Ittmann Bu kişi benim

Yayımlanma Tarihi 4 Nisan 2018
Gönderilme Tarihi 2 Ekim 2017
Kabul Tarihi 6 Kasım 2017
Yayımlandığı Sayı Yıl 2018 Cilt: 4 Sayı: 2

Kaynak Göster

AMA Karataş ÖF, Ittmann M. MicroRNA-33a levels do not correlate with the expression of its host gene SREBF2 and its isoforms in prostate cancer cell lines. Eur Res J. Nisan 2018;4(2):79-84. doi:10.18621/eurj.341363

e-ISSN: 2149-3189 


The European Research Journal, hosted by Turkish JournalPark ACADEMIC, is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

by-nc-nd.png

2024